Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Multiple Myeloma and Plasma Disorders

December 20, 2021

A collection of features and news articles published in ASH Clinical News related to multiple myeloma and plasma disorders.

Keywords:

Infection Risk Linked to Bispecific Antibody Use in Multiple Myeloma

A pooled analysis published in Blood Advances found that half of patients with multiple myeloma (MM) who were treated with bispecific antibodies developed an infection ...

Investigational BCMA-Directed CAR T-Cell Therapy for Relapsed or Refractory Multiple Myeloma Provides Deep Responses, Low Toxicity

A fractionated dose of ARI0002hm, an investigational autologous chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA), combined with a booster dose ...

New Strategy Boosts Anti-BCMA CAR T-Cell Activity for Patients with Multiple Myeloma

Adding crenigacestat, a γ-secretase inhibitor (GSI), to anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy was found to produce deep and durable responses ...

Cilta-Cel Bests Standard Care in Early Lenalidomide-Refractory MM

In patients with lenalidomide-refractory multiple myeloma (MM) who had received one to three previous therapies, a single infusion of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen ...

Final Analysis of CANDOR Trial Supports KdD as Standard of Care for R/R MM

The combination of carfilzomib, daratumumab, and dexamethasone (KdD) showed better overall survival (OS) and confirmed progression-free survival (PFS) in patients with ...

Isa-Kd Prolongs PFS to Almost Three Years in Early Relapsed MM Follow-up Study

In patients with early relapsed multiple myeloma (MM), the addition of the anti-CD38 antibody isatuximab (Isa) to carfilzomib-dexamethasone (Kd) maintained the improved progression-free survival ...

Phase II Linvoseltamab Study Confirms Efficacy in R/R MM

Linvoseltamab, a B-cell maturation antigen (BCMA) bispecific T-cell antibody, has shown efficacy in patients with relapsed or refractory multiple myeloma (R/R MM) in earlier reports ...

CAR-T Cells Manufactured With T-Charge Evaluated in R/R MM

In patients with heavily pretreated relapsed or refractory multiple myeloma (R/R MM) with aggressive disease, the T-Charge manufactured chimeric antigen receptor (CAR) T-cell therapy ...

Teclistamab Plus Talquetamab Produces Deep and Durable Responses in R/R MM, including EMD

In the first combination study of talquetamab and teclistamab in patients with relapsed or refractory multiple myeloma (R/R MM), the drug combination had a manageable safety profile ...

MRD-Adapted Treatment Identified Newly Diagnosed MM Patients for Intensification, Cessation

The use of measurable residual disease (MRD) to guide post-transplant consolidation and treatment cessation resulted in excellent outcomes for patients with standard or high-risk ...

 

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
July 2024

Advertisement intended for health care professionals

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals